Jacques Tapiero

Jacques Tapiero

Director/Board Member at MCCORMICK & COMPANY, INCORPORATED

Net worth: 2 M $ as of 30/05/2026

67 year
Health Technology
Consumer Non-Durables
Consumer Services

Profile

Jacques Tapiero is currently Independent Director at McCormick & Co., Inc. since 2012, Director at Esteve Pharmaceuticals SA, Lead Director at Esteve Healthcare SL since 2016, and Member-Global Council at Thunderbird School of Global Management since 2013.
Formerly, Mr. Tapiero was Managing Director at Eli Lilly Sweden AB from 1993 to 1995, Senior Vice President & President-Emerging Markets at Eli Lilly & Co. from 2011 to 2014, President & General Manager at Eli Lilly do Brasil Ltda.
from 1995 to 1999, and President & General Manager at Lilly France SAS from 2000 to 2004.
Education includes an MBA from Thunderbird School of Global Management conferred in 1982.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
07/06/2026 33,818 ( 0.23% ) 2 M $ 30/05/2026
26/04/2026 2,620 ( 0% ) 124 109 $ 30/05/2026

Jacques Tapiero active positions

CompaniesPositionStart
MCCORMICK & COMPANY, INCORPORATED Director/Board Member 23/09/2012
Corporate Officer/Principal 04/05/2011
Director/Board Member -
Director/Board Member 30/11/2016

Former positions of Jacques Tapiero

CompaniesPositionEnd
ELI LILLY AND COMPANY Corporate Officer/Principal 30/01/2014
Chief Executive Officer 31/12/2003
Chief Executive Officer 31/12/1998
Chief Executive Officer 31/12/1994
See the detail of Jacques Tapiero's experience

Training of Jacques Tapiero

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

85

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies8

Health Technology

Consumer Non-Durables

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Jacques Tapiero
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!